Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 47,015 shares, a decline of 59.2% from the October 31st total of 115,295 shares. Based on an average daily trading volume, of 29,406 shares, the days-to-cover ratio is currently 1.6 days.
Shares of Can-Fite BioPharma (NYSEAMERICAN CANF) traded down $0.01 during midday trading on Wednesday, reaching $1.41. The company’s stock had a trading volume of 7,248 shares, compared to its average volume of 57,471. Can-Fite BioPharma has a 52 week low of $1.31 and a 52 week high of $2.67.
CANF has been the subject of several research reports. Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of Can-Fite BioPharma in a report on Friday, September 1st. HC Wainwright set a $6.00 price objective on Can-Fite BioPharma and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, ValuEngine downgraded Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 7th.
About Can-Fite BioPharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can-Fite BioPharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.